Health Catalyst, Inc. (NASDAQ:HCAT) Short Interest Update

Health Catalyst, Inc. (NASDAQ:HCAT) saw a significant decrease in short interest in the month of November. As of November 15th, there was short interest totalling 2,530,000 shares, a decrease of 10.9% from the October 31st total of 2,840,000 shares. Based on an average trading volume of 485,300 shares, the days-to-cover ratio is presently 5.2 days.

Insider Buying and Selling

In other Health Catalyst news, COO Daniel Lesueur sold 8,137 shares of Health Catalyst stock in a transaction dated Wednesday, September 4th. The stock was sold at an average price of $7.58, for a total value of $61,678.46. Following the transaction, the chief operating officer now owns 140,108 shares in the company, valued at $1,062,018.64. The trade was a 5.49 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold a total of 26,568 shares of company stock valued at $203,405 over the last three months. 2.50% of the stock is owned by company insiders.

Institutional Trading of Health Catalyst

Hedge funds have recently added to or reduced their stakes in the company. Primecap Management Co. CA raised its position in shares of Health Catalyst by 14.7% in the second quarter. Primecap Management Co. CA now owns 2,379,462 shares of the company’s stock worth $15,205,000 after acquiring an additional 305,079 shares during the period. Janney Montgomery Scott LLC purchased a new position in shares of Health Catalyst in the 3rd quarter valued at about $897,000. Essex Investment Management Co. LLC acquired a new position in Health Catalyst in the 3rd quarter worth about $2,012,000. Millrace Asset Group Inc. purchased a new position in Health Catalyst during the third quarter worth approximately $1,568,000. Finally, AQR Capital Management LLC acquired a new stake in Health Catalyst in the second quarter valued at approximately $564,000. 85.00% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms recently commented on HCAT. Evercore ISI increased their target price on shares of Health Catalyst from $8.00 to $10.00 and gave the company an “outperform” rating in a research report on Tuesday, October 8th. JPMorgan Chase & Co. increased their price objective on Health Catalyst from $10.00 to $13.00 and gave the company an “overweight” rating in a report on Wednesday, September 4th. Citigroup boosted their target price on Health Catalyst from $9.00 to $10.50 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $16.00 price target on shares of Health Catalyst in a research note on Friday, October 4th. Finally, Stephens boosted their price target on Health Catalyst from $7.00 to $9.00 and gave the stock an “equal weight” rating in a research note on Thursday, November 14th. Three equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $11.79.

Health Catalyst Trading Up 2.2 %

Shares of NASDAQ HCAT traded up $0.19 during trading on Tuesday, reaching $9.02. 946,180 shares of the company traded hands, compared to its average volume of 496,222. The firm’s fifty day simple moving average is $8.12 and its 200 day simple moving average is $7.33. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.41 and a current ratio of 1.41. Health Catalyst has a 12-month low of $5.42 and a 12-month high of $11.41.

Health Catalyst (NASDAQ:HCAT) last announced its quarterly earnings results on Wednesday, November 6th. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.03). Health Catalyst had a negative net margin of 26.20% and a negative return on equity of 7.51%. The company had revenue of $76.40 million for the quarter, compared to analysts’ expectations of $76.27 million. During the same quarter in the prior year, the business posted ($0.22) earnings per share. The firm’s revenue was up 3.5% compared to the same quarter last year. As a group, equities analysts expect that Health Catalyst will post -0.33 earnings per share for the current year.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.